Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: Results from a retrospective cohort study

Thrombosis Research

Volumn 133, Issue 6, 2014, Pages 1045-1051

  Ramírez, Elena ^a   Romero Garrido, José A ^b   López Granados, Eduardo ^b   Borobia, Alberto M ^a   Pérez, Tamara ^b   Medrano, Nicolás ^a   Rueda, Cristina ^b   Tong, Hoi Y ^a   Herrero, Alicia ^b   Frías, Jesús ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Comorbidity; Immunoglobulin therapy; Incidence studies; Pharmacoepidemiology; Thromboembolism

Indexed keywords

ANTIANEMIC AGENT; DIURETIC AGENT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE THROMBOCYTOPENIA; CARDIOGENIC SHOCK; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CHILD; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DRUG DOSE COMPARISON; EATON LAMBERT SYNDROME; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFANT; INFECTION; ISCHEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NEUROPATHY; NEUTROPENIA; NEWBORN; OBSERVATIONAL STUDY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POLYARTERITIS NODOSA; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; VENOUS THROMBOEMBOLISM; VERY ELDERLY; WEGENER GRANULOMATOSIS; CHEMICALLY INDUCED; COMORBIDITY; INCIDENCE; MIDDLE AGED; PRESCHOOL CHILD; THROMBOEMBOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; YOUNG ADULT;

EID: 84900491089     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.03.046     Document Type: Article

References (50)

1. H. Orbach, U. Katz, Y. Sherer, and Y. Shoenfeld Intravenous immunoglobulin: adverse effects and safe administration Clin Rev Allergy Immunol 29 2005 173 184
2. Y. Sherer, Y. Levy, P. Langevitz, L. Rauova, F. Fabrizzi, and Y. Shoenfeld Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases Pharmacology 62 2001 133 137
3. L.R. Pierce, and N. Jain Risks associated with the use of intravenous immunoglobulin Transfus Med Rev 17 2003 241 251
4. M. Wittstock, R. Benecke, and U.K. Zettl Therapy with intravenous immunoglobulins: complications and side-effects Eur Neurol 50 2003 172 175
5. A. Ruetter, and T.A. Luger Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view Am J Clin Dermatol 5 2004 153 160
6. M. Osawa, F. Satoh, H. Horiuchi, W. Tian, N. Kugota, and I. Hasegawa Postmortem diagnosis of fatal anaphylaxis during intravenous administration of therapeutic and diagnostic agents: evaluation of clinical laboratory parameters and immunohistochemistry in three cases Leg Med (Tokyo) 10 2008 143 147
7. R. Rachid, and F.A. Bonilla The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature J Allergy Clin Immunol 129 2012 628 634
8. I. Marie, G. Maurey, F. Hervé, M.F. Hellot, and H. Levesque Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature Br J Dermatol 155 2006 714 721
9. F. Tufan, S. Kamali, B. Erer, A. Gul, M. Inanc, L. Ocal, M. Konice, and O. Aral Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases Clin Rheumatol 26 2007 1913 1915
10. G.G. Emerson, C.N. Herndon, and A.G. Sreih Thrombotic complications after intravenous immunoglobulin therapy in two patients Pharmacotherapy 22 2002 1638 1641
11. D. Paran, Y. Herishanu, O. Elkayam, L. Shopin, and R. Ben-Ami Venous and arterial thrombosis following administration of intravenous immunoglobulins Blood Coagul Fibrinolysis 16 2005 313 318
12. S. Vucic, P.S. Chong, K.T. Dawson, M. Cudkowicz, and D. Cros Thromboembolic complications of intravenous immunoglobulin treatment Eur Neurol 52 2004 141 144
13. U.S. Food and Drug Administration FDA interim statement regarding immune globulin intravenous (IGIV) 2009 2011
14. S.S. Haplea, J.T. Farrar, G.A. Gibson, M. Larkin, L.T. Pizzi, and A.K. Asbury Thromboembolic events associated with intravenous immunoglobulin therapy Neurology 48 1997 A54
15. Y.A. Rajabally, and D.A. Kearney Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study J Neurol Sci 308 2011 124 127
16. J.B. Caress, L. Hobson-Webb, L.V. Passmore, A.P. Finkbiner, and M.S. Cartwright Case-control study of thromboembolic events associated with IV immunoglobulin J Neurol 256 2009 339 342
17. F. Hsieh Sample size tables for logistic regression Stat Med 8 1989 795 802
18. D.J. Hamrock Adverse events associated with intravenous immunoglobulin therapy Int Immunopharmacol 6 2006 535 542
19. Y.J. Lee, J.U. Shin, J. Lee, K. Kim, W.S. Kim, and J.S. Ahn et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy J Korean Med Sci 22 2007 758 761
20. D.T. Alexandrescu, J.P. Dutcher, J.T. Hughes, J. Kaplan, and P.H. Wiernik Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol 78 2005 216 220
21. D. Hefer, and M. Jaloudi Thromboembolic events as an emerging adverse effect during high dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature Ann Hematol 84 2005 411 415
22. O. Elkayam, D. Paran, R. Milo, Y. Davidovitz, D. Almoznino-Sarafian, D. Zeltser, M. Yaron, and D. Caspi Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases Ann Rheum Dis 59 2000 77 80
23. S.B. Stenton, D. Dalen, and K. Wilbur Myocardial infarction associated with intravenous immune globulin Ann Pharmacother 39 2005 2114 2118
24. B.A. Steinberger, S.M. Ford, and T.A. Coleman Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia Am J Hematol 73 2003 97 100
25. R.J. Gordon, G.K. Snyder, H. Tritel, and W.J. Taylor Potential significance of plasma viscosity and hematocrit variations in myocardial ischemia Am Heart J 87 1974 175 182
26. R. Sztajzel, J. Le Floch-Rohr, and P. Eggimann High-dose intravenous immunoglobulin treatment and cerebral vasospasm: A possible mechanism of ischemic encephalopathy? Eur Neurol 41 1999 153 158
27. Information note of the Spanish Agency for Medicines and Health Products on withdrawal of all lots of Octagamoncta by an increased risk of thromboembolic events Accessed March 21, 2014 http://www.aemps.gob.es/informa/ notasInformativas/medicamentosUsoHumano/seguridad/2010/NI-2010-13-octagamocta. htm
28. A.S. Wolberg, R.H. Kon, D.M. Monroe, and M. Hoffman Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations Am J Hematol 65 2000 30 34
29. P.A. Merkel, G.H. Lo, J.T. Holbrook, A.K. Tibbs, N.B. Allen, and G.S. Davis Hoffman et al. Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study Ann Intern Med 142 2005 620 626
30. U. Katz, and Y. Shoenfeld Intravenous immunoglobulin therapy and thromboembolic complications Lupus 14 2005 802 808
31. J.S. Orange, E.M. Hossny, C.R. Weiler, M. Ballow, M. Berger, and F.A. Bonilla et al. Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology J Allergy Clin Immunol 117 Suppl. 4 2006 Apr S525 S553 [Review. Erratum in: J Allergy Clin Immunol 2006; 117:1483]
32. P. Imbach, H.P. Wagner, W. Berchtold, G. Gaedicke, A. Hirt, and P. Joller et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood Lancet 2 1985 464 468
33. E. Kansu Thrombosis in stem cell transplantation Hematology 17 Suppl. 1 2012 S159 S162
34. J. Labrador, L. Lopez-Anglada, E. Perez-Lopez, F.S. Lozano, L. Lopez-Corral, and F.M. Sanchez-Guijo et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients Haematologica 98 2013 437 443
35. K. Fukazawa, and E.A. Pretto Jr. Reversal of hypercoagulability with hydroxyethyl starch during transplantation: a case series J Clin Anesth 23 2011 61 65
36. Z. Aalamian Reducing adverse effects of immunosuppressive agents in kidney transplant recipients Prog Transplant 11 2001 271 282
37. M. Levi, M. Schultz, and T. van der Poll Sepsis and thrombosis Semin Thromb Hemost 39 2013 559 566
38. W.H. Reinhart, and P.E. Berchtold Effect of high-dose intravenous immunoglobulin therapy on blood rheology Lancet 339 1992 662 664
39. N. Evangelou, T. Littlewood, P. Anslow, and H. Chapel Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment J Clin Pathol 56 2003 308 309
40. K.A. Katz, C.M. Hivnor, D.E. Geist, M. Shapiro, M.E. Ming, and V.P. Werth Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions Arch Dermatol 139 2003 991 993
41. A. Zakarija, and H.C. Kwaan Adverse effects on hemostatic function of drugs used in hematologic malignancies Semin Thromb Hemost 33 2007 355 364
42. M. Fazio, M. Bardelli, F. Cominotto, F. Fiammengo, B. Fabris, and F. Fischetti et al. Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives Exp Gerontol 36 2001 571 581
43. H. Inoue Atarashi H; Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation Am J Cardiol 86 2000 852 855
44. E. Luna, I. Cerezo, G. Collado, C. Martinez, J. Villa, and R. Macias et al. Vascular thrombosis after kidney transplantation: predisposing factors and risk index Transplant Proc 42 2010 2928 2930
45. C. Gangireddy, J.R. Rectenwald, G.R. Upchurch, T.W. Wakefield, S. Khuri, and W.G. Henderson et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism J Vasc Surg 45 2007 335 341 [discussion 41-2]
46. G.D. Lowe Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease J Intern Med 256 2004 361 374
47. J. Bohlius, J. Wilson, J. Seidenfeld, M. Piper, G. Schwarzer, and J. Sandercock et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 2006 708 714
48. S.M. Zaacks, L. Klein, C.D. Tan, E.R. Rodriguez, and J.B. Leikin Hypersensitivity myocarditis associated with ephedra use J Toxicol Clin Toxicol 37 1999 485 489
49. R. Ramasubbu Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review J Clin Psychiatry 65 2004 1642 1653
50. H. Wallaschofski, M. Eigenthaler, M. Kiefer, M. Donne, B. Hentschel, and H.J. Gertz et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study J Clin Psychopharmacol 23 2003 479 483